X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3669) 3669
Publication (241) 241
Book Review (77) 77
Book Chapter (23) 23
Newsletter (9) 9
Magazine Article (7) 7
Conference Proceeding (5) 5
Newspaper Article (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
dabigatran (2883) 2883
index medicus (2533) 2533
humans (2457) 2457
warfarin (1991) 1991
rivaroxaban (1690) 1690
anticoagulants (1628) 1628
atrial fibrillation (1427) 1427
apixaban (1151) 1151
anticoagulants - therapeutic use (1101) 1101
stroke (1072) 1072
administration, oral (1068) 1068
male (936) 936
female (891) 891
anticoagulants - adverse effects (855) 855
anticoagulants - administration & dosage (848) 848
atrial fibrillation - drug therapy (832) 832
aged (830) 830
dabigatran etexilate (830) 830
cardiac & cardiovascular systems (793) 793
stroke - prevention & control (696) 696
prevention (691) 691
hematology (688) 688
atrial-fibrillation (679) 679
peripheral vascular disease (665) 665
venous thromboembolism (665) 665
hemorrhage - chemically induced (616) 616
atrial fibrillation - complications (594) 594
thromboembolism (591) 591
middle aged (566) 566
risk factors (556) 556
safety (542) 542
management (515) 515
stroke prevention (513) 513
pharmacology & pharmacy (502) 502
risk (480) 480
treatment outcome (469) 469
anticoagulation (465) 465
thrombin (450) 450
therapy (437) 437
beta-alanine - analogs & derivatives (436) 436
aged, 80 and over (429) 429
oral anticoagulants (427) 427
medicine, general & internal (423) 423
vitamin k - antagonists & inhibitors (419) 419
bleeding (402) 402
medicine & public health (402) 402
warfarin - therapeutic use (392) 392
cardiac arrhythmia (391) 391
benzimidazoles - therapeutic use (390) 390
analysis (383) 383
stroke - etiology (368) 368
direct thrombin inhibitor (354) 354
care and treatment (353) 353
edoxaban (350) 350
drug therapy (346) 346
pyrazoles - therapeutic use (337) 337
pyridones - therapeutic use (337) 337
cardiology (326) 326
hemorrhage (323) 323
abridged index medicus (322) 322
efficacy (317) 317
thrombosis (311) 311
dabigatran - therapeutic use (298) 298
patients (291) 291
antithrombotic therapy (276) 276
factor xa inhibitors (275) 275
warfarin - adverse effects (275) 275
benzimidazoles - adverse effects (273) 273
blood coagulation - drug effects (272) 272
direct oral anticoagulants (271) 271
dabigatran - adverse effects (264) 264
metaanalysis (259) 259
mortality (257) 257
pyridines - therapeutic use (252) 252
dosage and administration (251) 251
internal medicine (251) 251
benzimidazoles - administration & dosage (249) 249
double-blind (247) 247
anticoagulants - pharmacology (244) 244
factor xa inhibitor (243) 243
pharmacokinetics (242) 242
antithrombins - therapeutic use (240) 240
fibrillation (240) 240
thromboembolism - prevention & control (240) 240
beta-alanine - therapeutic use (234) 234
venous thromboembolism - drug therapy (233) 233
antithrombins - adverse effects (229) 229
dabigatran - administration & dosage (226) 226
thiophenes - therapeutic use (225) 225
morpholines - therapeutic use (224) 224
clinical trials (223) 223
surgery (222) 222
pyrazoles - administration & dosage (219) 219
adult (218) 218
pyridones - administration & dosage (218) 218
risk assessment (218) 218
prothrombin complex concentrate (217) 217
reversal (214) 214
thrombin - antagonists & inhibitors (212) 212
retrospective studies (211) 211
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3370) 3370
German (142) 142
French (64) 64
Spanish (61) 61
Russian (17) 17
Hungarian (9) 9
Italian (7) 7
Japanese (7) 7
Portuguese (7) 7
Polish (6) 6
Swedish (5) 5
Danish (3) 3
Norwegian (2) 2
Czech (1) 1
Dutch (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 03/2014, Volume 12, Issue 3, pp. 320 - 328
Journal Article
Circulation, ISSN 0009-7322, 2015, Volume 132, Issue 13, pp. 1252 - 1260
Background-The safety and effectiveness of non-vitamin K antagonist (VKA) oral anticoagulants, dabigatran or rivaroxaban, were compared with VKA in... 
atrial fibrillation | databases, factual | Databases | Factual | anticoagulants | comparative effectiveness research | France | stroke | hemorrhage | pharmacoepidemiology | CARDIAC & CARDIOVASCULAR SYSTEMS | ANTICOAGULATION CONTROL | METAANALYSIS | QUALITY | EFFICACY | SAFETY | PREVENTION | THERAPY | WARFARIN | ORAL ANTICOAGULANTS | PERIPHERAL VASCULAR DISEASE | Dabigatran - adverse effects | Follow-Up Studies | Humans | Middle Aged | Hospitalization - statistics & numerical data | Warfarin - adverse effects | Risk | Dabigatran - therapeutic use | Thrombophilia - etiology | Warfarin - therapeutic use | Young Adult | Vitamin K - antagonists & inhibitors | Rivaroxaban - adverse effects | Thromboembolism - prevention & control | Adult | Rivaroxaban - therapeutic use | Thrombophilia - drug therapy | Databases, Factual | Antithrombins - therapeutic use | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Thromboembolism - etiology | Anticoagulants - adverse effects | Arterial Occlusive Diseases - etiology | Factor Xa Inhibitors - therapeutic use | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Adolescent | Aged | Arterial Occlusive Diseases - prevention & control | Hemorrhage - chemically induced | Antagonists (Biochemistry) | Complications and side effects | Rivaroxaban | Atrial fibrillation | Dosage and administration | Thromboembolism | Drug therapy | Comparative analysis | Hemorrhage | Risk factors | 184 | Original | 185
Journal Article
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 10/2016, Volume 116, Issue 4, pp. 754 - 763
In the RE-LY clinical trial, dabigatran presented a better effectiveness/safety profile when compared to warfarin. However, clinical trials are not very... 
Dabigatran | Vitamin K antagonist | Atrial fibrillation | Real-world | Meta-analysis | POPULATION | SAFETY | RIVAROXABAN | meta-analysis | RISK | MYOCARDIAL ISCHEMIC EVENTS | vitamin K antagonist | INTRACRANIAL HEMORRHAGE | STROKE | real-world | WARFARIN | ORAL ANTICOAGULANTS | dabigatran | PERIPHERAL VASCULAR DISEASE | THROMBOEMBOLISM | HEMATOLOGY
Journal Article
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 03/2017, Volume 135, Issue 10, pp. e604 - e633
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 12/2016, Volume 68, Issue 24, pp. 2597 - 2604
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2017, Volume 69, Issue 23, pp. 2779 - 2790
Abstract Background Dose reduction of non–vitamin K antagonist oral anticoagulants (NOACs) is indicated in patients with atrial fibrillation (AF) with renal... 
Cardiovascular | Internal Medicine | kidney disease | dose | bleeding | embolism | stroke | CARDIAC & CARDIOVASCULAR SYSTEMS | SAFETY | RIVAROXABAN | RISK | APIXABAN | MDRD | CARE | COCKCROFT-GAULT | DABIGATRAN | WARFARIN | United States - epidemiology | Dabigatran - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Male | Antithrombins - administration & dosage | Rivaroxaban - administration & dosage | Factor Xa Inhibitors - administration & dosage | Incidence | Dose-Response Relationship, Drug | Young Adult | Pyridones - administration & dosage | Time Factors | Aged, 80 and over | Adult | Female | Renal Insufficiency - complications | Stroke - epidemiology | Retrospective Studies | Vitamin K | Stroke - prevention & control | Hemorrhage - epidemiology | Administration, Oral | Atrial Fibrillation - drug therapy | Atrial Fibrillation - complications | Treatment Outcome | Pyrazoles - administration & dosage | Stroke - etiology | Adolescent | Aged | Hemorrhage - chemically induced | Stroke (Disease) | Medical policy | Care and treatment | Atrial fibrillation | Health care industry | Anticoagulants (Medicine) | Kidney diseases | Medical research | Chronic kidney failure | Medicine, Experimental | Heart | Cardiac arrhythmia | Renal function | Embolisms | Indication | Impairment | Risk | Data bases | Bleeding | Training | Prevention | Confidence intervals | Fibrillation | Databases | Ischemia | Safety | Drug dosages | Anticoagulants | Dosing | Stroke | Statistical analysis | Regression | Labels | Hazards | Marking | Patients | Embolism | Disease prevention | Oral cavity | Renal failure | Health hazards | Clinical medicine | Kidney transplantation
Journal Article
Journal Article